Collaborations

Our Strategy

GeneCentric’s mission is to become a leader in the development and commercialization of technology that defines cancer drug responder populations and thereby enhances success in drug development.

We partner with pharmaceutical and biotechnology companies to identify the most complete spectrum of responder populations to their drugs and drug candidates across throughout the e drug development process. The efficacy of our Cancer Subtype Platform (CSP®) in bringing insight and intelligence to the challenging realm of drug development can be seen at all stages – from discovery and translational research, to clinical validation and commercialization, to repositioning clinical stage compounds and identifying new indications for existing drugs.

Through our alliances, we are able to create new intellectual property and provide the basis for developing companion diagnostics. We are also leveraging our CSP platform to acquire and create new intellectual property around the development of select existing compounds.

GeneCentric Adds Unique Value at Every Stage of Drug Development

Development Stage Involvement

Drive translational research to FIM through novel in-silico and in-vivo modeling

Enable clear segmentation of patients via subtyping during early drug development

Confirm subtype profilers as response biomarkers supporting accelerated drug, and companion diagnostic, development

Expand subtypes drug-response biomarkers in confirmatory and indication expansion studies to maximize market potential

Reposition and repurpose drugs by subtyping patients to reveal new or additional drug responder populations and commercial potential

GeneCentric has built its Cancer Subtyping Platform (CSP) by complementing our own internal expertise with a growing network of leading researchers, their research laboratories, and corresponding academic institutions. GeneCentric works with researchers and institutions to identify and advance the most promising, novel science relating to cancer and immune biology that lead to a greater understanding of disease development and expression.

By working with our collaborations, GeneCentric drives to translate these discoveries into breakthroughs that enable treatments for the most common and complex cancers. Our current collaborations are in the areas of cancer genomics and genetics, informatics, and numerous types of cancer.

UNC

UNC

The University of North Carolina at Chapel Hill, through the UNC School of Medicine and the UNC Lineberger Comprehensive Cancer Center are core collaborators for GeneCentric, in cooperation with the Perou Lab within the Department of Genetics, and the Hayes Lab within the Division of Hematology and Oncology, Department of Medicine.

Washington University

Washington University

Within Washington University School of Medicine’s Department of Head and Neck Oncologic Surgery, and in cooperation with Dr. Jose P. Zevallos, Associate Professor, Otolaryngology, GeneCentric has a core collaboration in the area of Head and Neck Cancer Research.

University of Tennessee

University of Tennessee

GeneCentric is establishing collaborations with The University of Tennessee Health Science Center, through the University of Tennessee West Institute for Cancer Research’s Department of Medicine and the Departments of Genetics, Genomics and Informatics.

St.Jude

St.Jude

GeneCentric is establishing collaborations with The University of Tennessee Health Science Center, through the University of Tennessee West Institute for Cancer Research’s Department of Medicine and the Departments of Genetics, Genomics and Informatics.

GeneCentric partners with pharmaceutical and biotechnology companies in order to support the development of their pre-clinical, early and late-stage, as well as commercially available therapeutic programs and platforms. Through our CSP® platform of cancer profilers, GeneCentric supports the full spectrum of drug development.

Beginning with in-silico and in-vivo (PDX or other) models, we are able to rapidly undertake pre-clinical validation of cancer subtypes for specific drug candidates/targets. Next, from first in man (FIM) or early-stage trials, to validation/mid-stage clinical studies, to late-stage or regulatory-submission trials, CSP® profilers enables patient stratification/optimization and transfer readily to companion diagnostics to achieve rapid and successful drug/diagnostic development. GeneCentric is dedicated to speeding drug development and increasing the rate of program success at each stage of the process.

Partner-LabCorp

Partner-LabCorp

LabCorp offers a lung classification test, HistoPlus™ to distinguish non-small cell lung from neuroendocrine tumors through an agreement with GeneCentric. LabCorp has also made an equity investment in GeneCentric.

Partner-BMS

Partner-BMS

Research collaboration to identify translational biomarkers for immuno-oncology therapeutic, Opdivo® (nivolumab) for potential use in future clinical trials. Bristol-Myers Squibb also made an equity investment in GeneCentric as part of the alliance.